Company profile
Oruka Therapeutics, Inc.
NASDAQ: ORKA · Healthcare · Biotechnology
PublicHQ Menlo Park, MACIK 0000907654Reports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
66BFH 66DQ 63GM —SS 79
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, filing timeliness
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$105.4M
Employees
68
as of 2026-08-08
Market cap
$6.0B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$105.4M-$105.4M2025
Operating income-$122.1M-$122.1M2025
Total assets$488.6M$488.6M2025
Liabilities$16.7M$16.7M2025
Equity$471.9M$471.9M2025
Revenue trend
FY2016 – FY2023 · USD
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Oruka Therapeutics, Inc.’s revenue?
Oruka Therapeutics, Inc. booked $0 in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Summit Therapeutics Inc.49DSpyre Therapeutics, Inc.64CPraxis Precision Medicines, Inc.61CScholar Rock Holding Corporation39DDenali Therapeutics Inc.52DViking Therapeutics, Inc.69BKey facts
CEOLawrence Otto Klein
SectorHealthcare
IndustryBiotechnology
HeadquartersMenlo Park, MA
ExchangeNASDAQ: ORKA
Employees68
IPO date1997-08-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.